A long-acting amylin analogue targeting a distinct satiety pathway from GLP-1, currently in Phase 3 trials as CagriSema when combined with semaglutide.
| Provider | Type | Price | Review | Link |
|---|---|---|---|---|
| NextGenPeps | Research | $99 / 10mg | — | Visit Site → |
Telehealth = physician-prescribed. Research = for research use only, no prescription required. Learn the difference →
Cagrilintide is a long-acting analogue of amylin, a peptide hormone co-secreted with insulin by pancreatic beta cells. Amylin works through a completely different signaling pathway than GLP-1 — acting centrally in the hindbrain to slow gastric emptying, suppress glucagon, and reduce food intake. This mechanistic distinction makes cagrilintide a valuable complement to GLP-1-based therapies.
Cagrilintide is being studied in combination with semaglutide under the name CagriSema (developed by Novo Nordisk). Phase 2 data showed the combination produced ~15% weight loss at 32 weeks — with Phase 3 trials ongoing as of 2026. The rationale for combining the two is additive satiety signaling through two independent pathways, potentially surpassing tirzepatide in weight reduction over time.
As a standalone agent, cagrilintide produces modest weight loss relative to GLP-1 drugs. Its primary value is in combination protocols. Research-use protocols typically dose at 0.16mg/week escalating to 2.4mg/week. The compound is currently available through research vendors only; no telehealth clinics prescribe it as a standalone.
Use code 3LUIZH10 at NextGenPeps for a discount on research-grade cagrilintide.